Anton Terasmaa Selected Research

Wolfram Syndrome (Syndrome, Wolfram)

11/2021	Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.
1/2021	Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model.
10/2019	GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome.
1/2018	Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.
11/2017	Glutathione system in Wolfram syndrome 1‑deficient mice.
1/2017	Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anton Terasmaa Research Topics

Disease

6	Wolfram Syndrome (Syndrome, Wolfram) 11/2021 - 01/2017
3	Glucose Intolerance 10/2019 - 09/2011
2	Inflammation (Inflammations) 01/2021 - 01/2018
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 11/2017
2	Atrophy 01/2021 - 01/2017
1	Disease Progression 11/2021
1	Sensorineural Hearing Loss 11/2021
1	Neoplasms (Cancer) 01/2021
1	Cognitive Dysfunction 01/2021
1	Neuroinflammatory Diseases 10/2019
1	Diabetes Mellitus 10/2019
1	Body Weight (Weight, Body) 09/2019
1	Dystonia (Limb Dystonia) 09/2019
1	Parkinsonian Disorders (Parkinsonism) 09/2019
1	Gliosis 01/2017
1	Weight Gain 01/2014
1	Bipolar Disorder (Manic Depressive Psychosis) 12/2011
1	Mood Disorders (Mood Disorder) 12/2011
1	Decapitation 06/2003
1	Schizophrenia (Dementia Praecox) 05/2002
1	Parkinson Disease (Parkinson's Disease) 05/2002
1	Neuroblastoma 05/2002

Drug/Important Bio-Agent (IBA)

4	Liraglutide FDA Link 11/2021 - 01/2018
2	Glucagon-Like Peptide-1 ReceptorIBA 10/2019 - 01/2018
2	Pharmaceutical PreparationsIBA 09/2019 - 01/2014
2	Insulin (Novolin)FDA Link 01/2018 - 01/2017
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2014 - 09/2011
1	SolutionsIBA 11/2021
1	Adenylate KinaseIBA 01/2021
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021
1	6,7-dihydroxyflavoneIBA 01/2021
1	Neuroprotective AgentsIBA 10/2019
1	Pseudoephedrine FDA LinkGeneric 09/2019
1	ManganeseIBA 09/2019
1	Acetic Acid (Vinegar)FDA LinkGeneric 09/2019
1	Potassium PermanganateIBA 09/2019
1	Illicit Drugs (Recreational Drugs)IBA 09/2019
1	manganese chloride (manganese chloride, tetrahydrate)FDA Link 09/2019
1	monomethylpropion (methcathinone)IBA 09/2019
1	Glucagon (Glukagon)FDA Link 01/2018
1	Glycoproteins (Glycoprotein)IBA 11/2017
1	Glutathione (Reduced Glutathione)IBA 11/2017
1	Retinaldehyde (Retinal)IBA 01/2017
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2014
1	Biological ProductsIBA 12/2011
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 12/2011
1	Glucose (Dextrose)FDA LinkGeneric 09/2011
1	Streptozocin (Streptozotocin)FDA Link 09/2011
1	DSP 4 (DSP-4)IBA 06/2003
1	NeurotoxinsIBA 06/2003
1	RacloprideIBA 06/2003
1	Dopamine (Intropin)FDA LinkGeneric 05/2002
1	Adenosine (Adenocard)FDA LinkGeneric 05/2002

Therapy/Procedure

1	Injections 09/2019
1	Lasers (Laser) 05/2002